EHS
EHS

Siga wins FDA nod for oral smallpox treatment

Siga TechnologiesSiga Technologies (NSDQ:SIGA) today won FDA approval for its oral formulation of tecovirimat as a treatment of smallpox in the case of a potential outbreak.

The drug is designed to mitigate the impact of a potential bioterrorism attack, according to the New York-based company. Siga also touted that the FDA granted its request for a priority review voucher, giving them the option for accelerated FDA review of a future product.

Get the full story at our sister site, Drug Delivery Business News.

The post Siga wins FDA nod for oral smallpox treatment appeared first on MassDevice.

EHS
Back to top button